Robert E Davis Selected Research

lumateperone

12/2021	Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial.
1/2021	A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia.
1/2021	Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia.
1/2020	Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial.
1/2019	Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia.
1/2016	ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial.
1/2016	ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes.
8/2015	ITI-007 demonstrates brain occupancy at serotonin 5-HT₂A and dopamine D₂ receptors and serotonin transporters using positron emission tomography in healthy volunteers.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert E Davis Research Topics

Disease

9	Schizophrenia (Dementia Praecox) 01/2021 - 02/2010
4	Infections 10/2017 - 01/2006
2	Sleepiness 12/2021 - 01/2021
2	Weight Gain 01/2021 - 01/2016
2	Inflammation (Inflammations) 01/2020 - 01/2016
2	Hypertension (High Blood Pressure) 03/2019 - 01/2016
2	Movement Disorders (Movement Disorder) 01/2019 - 02/2016
2	Cognitive Dysfunction 02/2016 - 02/2010
2	Alzheimer Disease (Alzheimer's Disease) 02/2016 - 02/2010
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2016 - 09/2012
2	Parkinson Disease (Parkinson's Disease) 10/2008 - 07/2003
2	Catalepsy 06/2008 - 08/2007
2	Psychotic Disorders (Schizoaffective Disorder) 09/2004 - 07/2003
1	Osteoporosis 01/2022
1	Nausea 12/2021
1	Skin Neoplasms (Skin Cancer) 05/2021
1	Body Weight (Weight, Body) 01/2021
1	Hyperemia 01/2021
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2021
1	Progeria (Hutchinson Gilford Syndrome) 01/2021
1	Headache (Headaches) 01/2021
1	Hypertrophy 01/2021
1	COVID-19 01/2021
1	Drug Overdose 06/2020
1	Opioid-Related Disorders (Opiate Addiction) 01/2020
1	Substance-Related Disorders (Drug Abuse) 01/2020
1	Heart Failure 03/2019
1	Obesity 03/2019
1	Psychomotor Agitation (Akathisia) 01/2019
1	Hyperprolactinemia 01/2019
1	Mood Disorders (Mood Disorder) 08/2015
1	Nervous System Diseases (Neurological Disorders) 03/2014
1	Necrosis 02/2014
1	Central Nervous System Diseases (CNS Diseases) 09/2012
1	Neoplasms (Cancer) 09/2012
1	Mitochondrial Diseases (Mitochondrial Disease) 09/2012
1	Autistic Disorder (Autism) 09/2012
1	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2010
1	Polyuria 10/2008
1	Neurogenic Diabetes Insipidus (Central Diabetes Insipidus) 10/2008
1	Dyskinesias (Dyskinesia) 10/2008
1	Tremor (Tremors) 10/2008

Drug/Important Bio-Agent (IBA)

8	lumateperoneIBA 12/2021 - 08/2015
5	Antipsychotic Agents (Antipsychotics)IBA 01/2021 - 07/2003
5	Investigational DrugsIBA 02/2016 - 03/2014
4	Serotonin (5 Hydroxytryptamine)IBA 01/2021 - 10/2008
3	Glutamic Acid (Glutamate)FDA Link 01/2021 - 01/2019
3	Pharmaceutical PreparationsIBA 01/2021 - 09/2012
3	Dopamine (Intropin)FDA LinkGeneric 01/2021 - 01/2019
3	16S Ribosomal RNAIBA 10/2017 - 01/2006
3	5-HT2A Serotonin Receptor (5 HT2A Receptor)IBA 01/2010 - 07/2003
2	CholesterolIBA 01/2021 - 01/2016
2	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 01/2021 - 02/2016
2	ProlactinIBA 01/2021 - 01/2016
2	ITI-214IBA 01/2021 - 01/2020
2	Biological ProductsIBA 01/2021 - 01/2016
2	Opioid Analgesics (Opioids)IBA 06/2020 - 01/2020
2	Risperidone (Risperdal Consta)FDA LinkGeneric 01/2016 - 08/2007
2	Proteins (Proteins, Gene)FDA Link 02/2014 - 09/2012
2	4- (3- (4- butylpiperidin- 1- yl)propyl)- 7- fluoro- 4H- benzo(1,4)oxazin- 3- oneIBA 02/2010 - 06/2008
2	pimavanserinIBA 10/2008 - 08/2007
2	Haloperidol (Haldol)FDA LinkGeneric 06/2008 - 08/2007
1	CalciumIBA 01/2022
1	Sunscreening Agents (Sunscreens)IBA 05/2021
1	LDL CholesterolIBA 01/2021
1	CytokinesIBA 01/2021
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2021
1	COVID-19 VaccinesIBA 01/2021
1	Neurotransmitter Agents (Neurotransmitter)IBA 01/2021
1	Indicators and Reagents (Reagents)IBA 01/2020
1	Cocaine (Cocaine HCl)IBA 01/2020
1	LipidsIBA 03/2019
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2019
1	QuinoxalinesIBA 03/2014
1	RNA (Ribonucleic Acid)IBA 02/2014
1	Vasopressins (Vasopressin)IBA 10/2008
1	Peptides (Polypeptides)IBA 10/2008
1	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 10/2008
1	PyrrolidinesIBA 10/2008
1	Tacrine (Cognex)FDA Link 10/2008
1	SaltsIBA 10/2008
1	Urea (Carbamide)FDA LinkGeneric 10/2008
1	Levodopa (L Dopa)FDA LinkGeneric 10/2008
1	Amphetamine (Amfetamine)FDA LinkGeneric 06/2008
1	Apomorphine FDA Link 06/2008
1	2- (4- methoxyphenyl)- N- (4- methylbenzyl)- N- (1- methylpiperidin- 4- yl)acetamideIBA 09/2004

Therapy/Procedure

1	Baths 01/2021
1	Drug Therapy (Chemotherapy) 01/2021
1	Polypharmacy 03/2019
1	Therapeutics 07/2003